<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59028">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337556</url>
  </required_header>
  <id_info>
    <org_study_id>13.23.CLI</org_study_id>
    <nct_id>NCT02337556</nct_id>
  </id_info>
  <brief_title>The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU</brief_title>
  <official_title>The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the nutritional effect on blood glucose of two commercially available enteral
      diets in overweight or obese patients in the Intensive Care Unit.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose variability - Number of glycemic events outside the serum glucose range of 110-150 mg/dl</measure>
    <time_frame>First seven days in the ICU</time_frame>
    <description>Number of glycemic events outside the serum glucose range of 110-150 mg/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose variability - Number of glycemic events between 80-110 mg/dl and 150-180 mg/dl</measure>
    <time_frame>First seven days in the ICU</time_frame>
    <description>Number of glycemic events between 80-110 mg/dl and 150-180 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability - Number of episodes of hypoglycemia (glucose &lt; 80 mg/dl)</measure>
    <time_frame>First seven days in the ICU</time_frame>
    <description>Number of episodes of hypoglycemia (glucose &lt; 80 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability - Number of episodes of hyperglycemia (glucose &gt; 180 mg/dl)</measure>
    <time_frame>First seven days in the ICU</time_frame>
    <description>Number of episodes of hyperglycemia (glucose &gt; 180 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability - Average glucose levels</measure>
    <time_frame>First seven days in the ICU</time_frame>
    <description>Average glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for exogenous insulin administration</measure>
    <time_frame>First seven days in the ICU</time_frame>
    <description>Number of administrations, amount of insulin received, number of times insulin order adjusted, circulating C-peptide at baseline, day 3, 5 and 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for exogenous glucose administration</measure>
    <time_frame>First seven days in the ICU</time_frame>
    <description>Number of times of administration and amount of glucose received</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nursing time</measure>
    <time_frame>First seven days in the ICU</time_frame>
    <description>Time required to monitor glucose levels and adjust insulin regimens in subset of patients studied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Critically Ill Mechanically Ventilated Subjects</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peptamen Bariatric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Replete</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peptamen Bariatric</intervention_name>
    <description>Commercially available enteral diet</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Replete</intervention_name>
    <description>Commercially available enteral diet</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New admit to the ICU and expected to remain in ICU 7 days

          -  Ventilator dependent at admission

          -  Requiring tube feeding enteral nutrition (EN) 7 days

          -  Expected to receive 50% of caloric needs within 72 hours

          -  Body Mass Index 26-45

        Exclusion Criteria:

          -  Trauma patients

          -  Major surgery in past 30 days or planned for next 7 days

          -  Diabetes mellitus (DM) type 1

          -  Admitted with diagnosis of diabetic ketoacidosis as primary diagnosis

          -  History of insulin requiring DM prior to admission to hospital

          -  Pregnant or lactating

          -  Non-functioning GI tract

          -  Use of parenteral nutrition in past 30 days

          -  Admitted with burns &gt; 20% body surface area

          -  Traumatic brain injury

          -  Hemodynamic instability that prevents delivery of EN &gt; 24hr

          -  Unable to access GI tract for feeding via tube, unable to receive EN

          -  Other contraindication to tube feeding

          -  Any other condition that would not allow patient to complete the study protocol

          -  Use of enteral formula at enrollment that cannot be changed to the investigational
             product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ileana M Alexander, RN, MBA</last_name>
    <phone>201-259-6794</phone>
    <email>ileana.alexander@rd.nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Jones, PhD, RD</last_name>
      <phone>404-727-5806</phone>
    </contact>
    <investigator>
      <last_name>Thomas Ziegler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Albert B. Chandler Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Kimbrough, RN</last_name>
      <phone>859-323-6346</phone>
      <phone_ext>247</phone_ext>
    </contact>
    <investigator>
      <last_name>Andrew Bernard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Flores, RN</last_name>
      <phone>336-713-0008</phone>
    </contact>
    <investigator>
      <last_name>Peter Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Hays, RN</last_name>
      <phone>615-429-3950</phone>
    </contact>
    <investigator>
      <last_name>Todd Rice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 8, 2016</lastchanged_date>
  <firstreceived_date>January 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
